These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 21550274

  • 1. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 18 cases, including histopathologic relationship with sclerosing epithelioid fibrosarcoma in a subset of cases.
    Rekhi B, Deshmukh M, Jambhekar NA.
    Ann Diagn Pathol; 2011 Oct; 15(5):303-11. PubMed ID: 21550274
    [Abstract] [Full Text] [Related]

  • 2. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement.
    Doyle LA, Wang WL, Dal Cin P, Lopez-Terrada D, Mertens F, Lazar AJ, Fletcher CD, Hornick JL.
    Am J Surg Pathol; 2012 Oct; 36(10):1444-51. PubMed ID: 22982887
    [Abstract] [Full Text] [Related]

  • 3. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group.
    Guillou L, Benhattar J, Gengler C, Gallagher G, Ranchère-Vince D, Collin F, Terrier P, Terrier-Lacombe MJ, Leroux A, Marquès B, Aubain Somerhausen Nde S, Keslair F, Pedeutour F, Coindre JM.
    Am J Surg Pathol; 2007 Sep; 31(9):1387-402. PubMed ID: 17721195
    [Abstract] [Full Text] [Related]

  • 4. Hyalinizing spindle cell tumor with giant rosettes and low-grade fibromyxoid sarcoma: an immunohistochemical and ultrastructural comparative investigation.
    Franchi A, Massi D, Santucci M.
    Ultrastruct Pathol; 2003 Sep; 27(5):349-55. PubMed ID: 14708726
    [Abstract] [Full Text] [Related]

  • 5. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma.
    Doyle LA, Möller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL.
    Am J Surg Pathol; 2011 May; 35(5):733-41. PubMed ID: 21415703
    [Abstract] [Full Text] [Related]

  • 6. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas.
    Folpe AL, Lane KL, Paull G, Weiss SW.
    Am J Surg Pathol; 2000 Oct; 24(10):1353-60. PubMed ID: 11023096
    [Abstract] [Full Text] [Related]

  • 7. Low-grade fibromyxoid sarcoma: Clinical, morphologic and genetic features.
    Mohamed M, Fisher C, Thway K.
    Ann Diagn Pathol; 2017 Jun; 28():60-67. PubMed ID: 28648941
    [Abstract] [Full Text] [Related]

  • 8. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up.
    Evans HL.
    Am J Surg Pathol; 2011 Oct; 35(10):1450-62. PubMed ID: 21921785
    [Abstract] [Full Text] [Related]

  • 9. Low-grade fibrosarcoma--report on 39 not otherwise specified cases and comparison with defined low-grade fibrosarcoma types.
    Hansen T, Katenkamp K, Brodhun M, Katenkamp D.
    Histopathology; 2006 Aug; 49(2):152-60. PubMed ID: 16879392
    [Abstract] [Full Text] [Related]

  • 10. Primary Renal Hybrid Low-grade Fibromyxoid Sarcoma-Sclerosing Epithelioid Fibrosarcoma: An Unusual Pediatric Case With EWSR1-CREB3L1 Fusion.
    Mok Y, Pang YH, Sanjeev JS, Kuick CH, Chang KT.
    Pediatr Dev Pathol; 2018 Aug; 21(6):574-579. PubMed ID: 29426275
    [Abstract] [Full Text] [Related]

  • 11. Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period.
    Bahrami A, Folpe AL.
    Am J Surg Pathol; 2010 Oct; 34(10):1504-13. PubMed ID: 20829680
    [Abstract] [Full Text] [Related]

  • 12. The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma.
    Panagopoulos I, Storlazzi CT, Fletcher CD, Fletcher JA, Nascimento A, Domanski HA, Wejde J, Brosjö O, Rydholm A, Isaksson M, Mandahl N, Mertens F.
    Genes Chromosomes Cancer; 2004 Jul; 40(3):218-28. PubMed ID: 15139001
    [Abstract] [Full Text] [Related]

  • 13. [Low-grade fibromyxoid sarcoma: a clinicopathological analysis of 9 cases].
    Lin J, Wang J, Yu LJ, Ying XL.
    Zhonghua Bing Li Xue Za Zhi; 2009 May; 38(5):302-6. PubMed ID: 19575871
    [Abstract] [Full Text] [Related]

  • 14. Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma.
    Arbajian E, Puls F, Magnusson L, Thway K, Fisher C, Sumathi VP, Tayebwa J, Nord KH, Kindblom LG, Mertens F.
    Am J Surg Pathol; 2014 Jun; 38(6):801-8. PubMed ID: 24441665
    [Abstract] [Full Text] [Related]

  • 15. Low-grade fibromyxoid sarcoma versus low-grade myxofibrosarcoma in the extremities and trunk. A comparison of clinicopathological and immunohistochemical features.
    Oda Y, Takahira T, Kawaguchi K, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Iwamoto Y, Tsuneyoshi M.
    Histopathology; 2004 Jul; 45(1):29-38. PubMed ID: 15228441
    [Abstract] [Full Text] [Related]

  • 16. Sclerosing epithelioid fibrosarcoma.
    Patterson JW, Tchernev G, Chokoeva AA, Wick MR.
    Wien Med Wochenschr; 2017 Apr; 167(5-6):120-123. PubMed ID: 27631873
    [Abstract] [Full Text] [Related]

  • 17. Sclerosing epithelioid fibrosarcoma of the oral cavity.
    Elkins CT, Wakely PE.
    Head Neck Pathol; 2011 Dec; 5(4):428-31. PubMed ID: 21691827
    [Abstract] [Full Text] [Related]

  • 18. Low-grade fibromyxoid sarcoma of the small intestine: report of 4 cases with molecular cytogenetic confirmation.
    Laurini JA, Zhang L, Goldblum JR, Montgomery E, Folpe AL.
    Am J Surg Pathol; 2011 Jul; 35(7):1069-73. PubMed ID: 21677541
    [Abstract] [Full Text] [Related]

  • 19. A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low-grade fibromyxoid sarcoma: a pathologic and molecular study of 18 cases.
    Prieto-Granada C, Zhang L, Chen HW, Sung YS, Agaram NP, Jungbluth AA, Antonescu CR.
    Genes Chromosomes Cancer; 2015 Jan; 54(1):28-38. PubMed ID: 25231134
    [Abstract] [Full Text] [Related]

  • 20. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.
    Blay JY, Tlemsani C, Toulmonde M, Italiano A, Rios M, Bompas E, Valentin T, Duffaud F, Le Nail LR, Watson S, Firmin N, Dubray-Longeras P, Ropars M, Perrin C, Hervieu A, Lebbe C, Saada-Bouzid E, Soibinet P, Fiorenza F, Bertucci F, Boudou P, Vaz G, Bonvalot S, Honoré C, Marec-Berard P, Minard V, Cleirec M, Biau D, Meeus P, Babinet A, Dumaine V, Carriere S, Fau M, Decanter G, Gouin F, Ngo C, Le Loarer F, Karanian M, Meurgey A, Dufresne A, Brahmi M, Chemin-Airiau C, Ducimetiere F, Penel N, Le Cesne A, NETSARC/REPPS/RESOS and French Sarcoma Group- Groupe d′Etude des Tumeurs Osseuses (GSF-GETO) networks.
    Eur J Cancer; 2024 Jan; 196():113454. PubMed ID: 38008029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.